Get the Stockscreener App
92.51
1.67%
1.52
Oruka Therapeutics Inc stock is traded at $92.51, with a volume of 600.47K.
It is up +1.67% in the last 24 hours and down -5.73% over the past month.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
See More
Previous Close:
$90.99
Open:
$90.06
24h Volume:
600.47K
Relative Volume:
0.48
Market Cap:
$6.13B
Revenue:
-
Net Income/Loss:
$-116.25M
P/E Ratio:
-38.69
EPS:
-2.3912
Net Cash Flow:
$-91.19M
1W Performance:
+1.50%
1M Performance:
-5.73%
6M Performance:
+164.39%
1Y Performance:
+517.97%
1-Day Range:
$89.38
$94.00
1-Week Range:
$86.00
$96.20
52-Week Range:
$14.66
$115.52
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
92.51 | 6.94B | 0 | -116.25M | -91.19M | -2.3912 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Piper Sandler | Overweight |
| Nov-13-25 | Initiated | Jefferies | Buy |
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Barclays | Overweight |
| May-22-25 | Initiated | BTIG Research | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Oruka Therapeutics Files $1 Billion Mixed Shelf - marketscreener.com
Oruka Therapeutics Inc aStock (AORKA) Price Prediction for 2026 to 2031 - Bybit
Show Me The Money: ORKA Makes A Splash With A 500%+ Gain; More Catalysts Ahead - RTTNews
Oruka (ORKA) Outlook: Finishes 4.40% Lower at $104.86 in the Current Update; Level Watch: Support at $99.62 and Resistance at $110.10 Frame the Range at the CloseFRAMA Signal - Vinanet
RTW Investments, LP Expands Oruka Therapeutics (ORKA) Stake with Strategic Add - GuruFocus
Oruka (ORKA) Earnings Snapshot: The Available Earnings Metric Delivers a Miss in the Available Record; Post-Report: Shares Finish 3.00% Down for the Current SessionEarnings Cycle Outlook - Vinanet
Preferred dividends of Oruka Therapeutics, Inc. – HAM:HQ1 - TradingView
Oruka Therapeutics, Inc. Income Statement – HAM:HQ1 - TradingView
Oruka Therapeutics (ORKA) Is Up 8.0% After Wider Q2 Net LossesHas The Bull Case Changed? - simplywall.st
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Oruka Therapeutics CMO Joana Goncalves sells $782,882 in stock - Investing.com
Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 52-Week HighWhat's Next? - MarketBeat
ORKA Q2 2026 Earnings: Wider Loss Reflects R&D Investment as Pre-Revenue Biotech Advances PipelineEarnings Power Value - Vinanet
Biotech Stocks At 52-Week HighsETON +44%, DXCM, ORKA, CON, ATAI - RTTNews
Oruka Therapeutics (NASDAQ:ORKA) Cut to "Sell" at Wall Street Zen - MarketBeat
LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $175 - Moomoo
ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - Stocktwits
Oruka Therapeutics stock hits 52-week high at 109.56 USD By Investing.com - Investing.com South Africa
Oruka Therapeutics GC Paul Quinlan sells $5.64m stock By Investing.com - Investing.com Canada
Oruka Therapeutics GC Paul Quinlan sells $5.64m stock - Investing.com
Oruka Therapeutics senior vice president Arjun Agarwal sells $1.06m By Investing.com - Investing.com Australia
Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 10,000 Shares of Stock - MarketBeat
Oruka Therapeutics senior vice president Arjun Agarwal sells $1.06m - Investing.com
Oruka Therapeutics Insider Sold Shares Worth $5,641,409, According to a Recent SEC Filing - marketscreener.com
Oruka Therapeutics Insider Sold Shares Worth $1,066,572, According to a Recent SEC Filing - marketscreener.com
Oruka Therapeutics (ORKA): Venrock group reports 7.4% ownership stake - Stock Titan
ORKA (ORKA) insider Paul Quinlan files to sell 71,000 shares via option exercise - Stock Titan
Viking Global group discloses 1.50M Oruka (ORKA) shares on amended 13G - Stock Titan
Oruka Therapeutics stock hits 52-week high at 109.56 USD - Investing.com
Oruka Therapeutics (ORKA) gains 5.2% stake holder with 3.14M shares - Stock Titan
Handelsbanken Fonder AB Purchases Shares of 160,900 Oruka Therapeutics, Inc. $ORKA - MarketBeat
Sei Investments Co. Raises Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Oruka Therapeutics (ORKA) On Its Earnings Miss And Whether The Valuation Still Holds - Sahm
A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $133 to $180 - Moomoo
Dimensional Fund Advisors LP Makes New Investment in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Capital World Investors (ORKA) reports 5.6% beneficial stake in Oruka Therapeutics - Stock Titan
Wedbush Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $165 - Moomoo
Oruka Therapeutics (ORKA) Is Up 10.9% After Wider-Than-Expected Q2 Loss From R&D InvestmentHas The Bull Case Changed? - simplywall.st
Oruka Therapeutics' (ORKA) "Buy" Rating Reaffirmed at Guggenheim - MarketBeat
Oruka Therapeutics' (ORKA) Outperform Rating Reiterated at Wedbush - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Given "Buy" Rating at BTIG Research - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month HighStill a Buy? - MarketBeat
ORUKA THERAPEUTICS INC : LEERINK PARTNERS RAISES TARGET PRICE TO $179 FROM $162 - Bitget
Oruka Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Oruka Therapeutics Q2 Loss Widens - marketscreener.com
Oruka Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Oruka Therapeutics Q2 EPS of $(0.55) misses estimates - scanx.trade
Oruka Therapeutics (NASDAQ:ORKA) Issues Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
Earnings Flash (ORKA) Oruka Therapeutics Posts Q2 Loss $0.55 a Share, vs. FactSet Est of $0.53 Loss - marketscreener.com
Oruka Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Oruka Therapeutics Inc Stock (ORKA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oruka Therapeutics Inc Stock (ORKA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sandler Laura Lee | Chief Operating Officer |
Sep 01 '26 |
Sale |
91.82 |
5,000 |
459,101 |
236,384 |
| Klein Lawrence Otto | Chief Executive Officer |
Sep 01 '26 |
Option Exercise |
7.80 |
75,000 |
585,000 |
1,000,580 |
| Klein Lawrence Otto | Chief Executive Officer |
Sep 01 '26 |
Sale |
91.83 |
75,000 |
6,887,484 |
925,580 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):